Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...

In the original lentivirus vectors described by Naldini et al (Naldini et al., 1996a) (Naldini et al., 1996b) , the vector pCMVΔR8.2 supplies all but the HIV envelope in trans, the vector pMD.G is ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

The popularity of viral vector-based gene therapies and vaccines is rapidly ... Download this application note from Thermo Fisher Scientific to learn how scientists have used their lentiviral ...

Download this application note to receive step-by-step guidance about optimizing and standardizing scalable lentiviral vector production and clarification.